LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Search

Revvity Inc

Closed

SectorHealthcare

102.71 -1.65

Overview

Share price change

24h

Current

Min

102.25

Max

104.4

Key metrics

By Trading Economics

Income

-8.6M

47M

Sales

-21M

699M

P/E

Sector Avg

54.418

79.874

EPS

0.4

Dividend yield

0.28

Profit margin

6.675

Employees

11,000

EBITDA

-14M

181M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+6.41% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

0.28%

2.31%

Next Ex Dividend date

16 sty 2026

Market Stats

By TradingEconomics

Market Cap

976M

12B

Previous open

104.36

Previous close

102.71

News Sentiment

By Acuity

31%

69%

89 / 374 Ranking in Healthcare

Revvity Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

1 gru 2025, 21:16 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 gru 2025, 18:51 UTC

Major Market Movers

Shopify Stock Falls on Cyber Monday System Outages

1 gru 2025, 23:47 UTC

Market Talk

Nikkei May Rise on Bargain Hunting -- Market Talk

1 gru 2025, 23:27 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 gru 2025, 23:26 UTC

Acquisitions, Mergers, Takeovers

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 gru 2025, 23:25 UTC

Acquisitions, Mergers, Takeovers

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 gru 2025, 21:52 UTC

Acquisitions, Mergers, Takeovers

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 gru 2025, 21:42 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 gru 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 gru 2025, 21:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 gru 2025, 21:41 UTC

Market Talk

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 gru 2025, 20:15 UTC

Market Talk

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 gru 2025, 20:00 UTC

Acquisitions, Mergers, Takeovers

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 gru 2025, 18:54 UTC

Market Talk

Silver Hits New Record As Momentum Continues -- Market Talk

1 gru 2025, 18:46 UTC

Market Talk

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 gru 2025, 16:41 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1 gru 2025, 16:41 UTC

Market Talk

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 gru 2025, 16:20 UTC

Market Talk

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 gru 2025, 16:00 UTC

Earnings

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 gru 2025, 15:51 UTC

Acquisitions, Mergers, Takeovers

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 gru 2025, 15:47 UTC

Market Talk

Global Equities Roundup: Market Talk

1 gru 2025, 15:47 UTC

Market Talk

Airbus Guidance Is at Risk -- Market Talk

1 gru 2025, 15:46 UTC

Acquisitions, Mergers, Takeovers

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 gru 2025, 15:33 UTC

Market Talk

Airbus Selloff May Be Overdone -- Market Talk

1 gru 2025, 15:26 UTC

Market Talk

Warming Forecast Pressures Natural Gas -- Market Talk

1 gru 2025, 15:23 UTC

Market Talk

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 gru 2025, 14:59 UTC

Acquisitions, Mergers, Takeovers

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Peer Comparison

Price change

Revvity Inc Forecast

Price Target

By TipRanks

6.41% upside

12 Months Forecast

Average 111.1 USD  6.41%

High 125 USD

Low 100 USD

Based on 11 Wall Street analysts offering 12 month price targets forRevvity Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

11 ratings

8

Buy

3

Hold

0

Sell

Sentiment

By Acuity

89 / 374 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat